Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Center for Human Genetics, |
RCV000659967 | SCV000781879 | likely pathogenic | Neurofibromatosis, type 1 | 2016-11-01 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV000659967 | SCV001216285 | pathogenic | Neurofibromatosis, type 1 | 2020-10-15 | criteria provided, single submitter | clinical testing | For these reasons, this variant has been classified as Pathogenic. Donor and acceptor splice site variants typically lead to a loss of protein function (PMID: 16199547), and loss-of-function variants in NF1 are known to be pathogenic (PMID: 10712197, 23913538). Disruption of this splice site has been observed in several individuals affected with neurofibromatosis type 1 (PMID: 21354044, 22190595). ClinVar contains an entry for this variant (Variation ID: 547571). This variant is not present in population databases (ExAC no frequency). This sequence change affects a donor splice site in intron 7 of the NF1 gene. It is expected to disrupt RNA splicing and likely results in an absent or disrupted protein product. |
Genome- |
RCV000659967 | SCV002561597 | likely pathogenic | Neurofibromatosis, type 1 | 2022-03-15 | criteria provided, single submitter | clinical testing | |
Swedish National Chi |
RCV004797853 | SCV005419202 | pathogenic | NF1-related disorder | 2024-05-01 | criteria provided, single submitter | clinical testing |